PXMD
NASDAQPaxMedica Inc.
News25/Ratings0
Latest news
25 items- SECPaxMedica Inc. filed SEC Form 8-K: Leadership Update8-K - PaxMedica, Inc. (0001811623) (Filer)
- PRPaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other ConditionsBOSTON, MA / ACCESSWIRE / January 14, 2025 / PaxMedica, Inc. (OTC:PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, is pleased to announce it has received a Notification to Grant Patent Right for Chinese Invention Patent Application No: 2020800553323, Compositions and methods for treating cognitive, social, or behavioral disabilities and neurodevelopmental disorders, such as those found in individuals impacted by autism.Howard Weisman, CEO of PaxMedica commented, "This is an extraordinary milestone for PaxMedica, as this is the first jurisdiction in the world where intellectual property protection of any form of suramin has been a
- 13D/GAmendment: SEC Form SC 13G/A filed by PaxMedica Inc.SC 13G/A - PaxMedica, Inc. (0001811623) (Subject)
- SECSEC Form NT 10-Q filed by PaxMedica Inc.NT 10-Q - PaxMedica, Inc. (0001811623) (Filer)
- SECSEC Form EFFECT filed by PaxMedica Inc.EFFECT - PaxMedica, Inc. (0001811623) (Filer)
- SECSEC Form S-1 filed by PaxMedica Inc.S-1 - PaxMedica, Inc. (0001811623) (Filer)
- SECSEC Form 10-Q filed by PaxMedica Inc.10-Q - PaxMedica, Inc. (0001811623) (Filer)
- SECPaxMedica Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Financial Statements and Exhibits8-K - PaxMedica, Inc. (0001811623) (Filer)
- PRPaxMedica Secures Immediate Exercise of WarrantsTARRYTOWN, NY / ACCESSWIRE / September 3, 2024 / PaxMedica, Inc. (OTC:PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 4,423,080 shares of common stock of the originally issued in November 2023, having an exercise price of 1.30 per share, at a reduced exercise price of $0.20 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (No. 333-275416). The offering is expected to close on or about
- PRPaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness InfectionCompany provides update on regulatory progress towards US NDA submission TARRYTOWN, NY / ACCESSWIRE / August 27, 2024 / PaxMedica, Inc. (OTC:PINKPXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, is pleased to announce a significant milestone in its global health efforts. The Malawi Ministry of Health has informed the company that a patient suffering from the potentially fatal parasitic infection known as Human Africa Trypanosomiasis Brucei Rhodesiense, (HAT), commonly referred to as African Sleeping Sickness, has recently received treatment with PAX-101, an intravenous form of Suramin, and is recovering at home. The Rhodesiense st
- SECSEC Form NT 10-Q filed by PaxMedica Inc.NT 10-Q - PaxMedica, Inc. (0001811623) (Filer)
- SECPaxMedica Inc. filed SEC Form 8-K: Leadership Update8-K - PaxMedica, Inc. (0001811623) (Filer)
- SECPaxMedica Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - PaxMedica, Inc. (0001811623) (Filer)
- SECPaxMedica Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - PaxMedica, Inc. (0001811623) (Filer)
- SECPaxMedica Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - PaxMedica, Inc. (0001811623) (Filer)
- PRPaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101TARRYTOWN, New York, May 15, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (the "Company" or "PaxMedica") (OTC:PXMD), a biopharmaceutical company dedicated to advancing treatments for neurological disorders, today announced it has timely filed a formal notice of appeal with the Nasdaq Office of Appeals and Review to reverse the decision of a Nasdaq Hearings Panel to delist the Company from Nasdaq. Following receipt of notification from Nasdaq on April 30th, PaxMedica determined to appeal the decision and intends to maintain that the Hearings Panel did not consider sufficiently or appropriately crucial aspects of PaxMedica's recent achievements and ongoing actions to regain compliance
- SECSEC Form 10-Q filed by PaxMedica Inc.10-Q - PaxMedica, Inc. (0001811623) (Filer)
- PRPaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory StrategyTARRYTOWN, New York, May 07, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (OTC:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, provided a corporate update in light of its transition off the NASDAQ stock market, emphasizing this change will not affect the company's commitment to advancing treatments for neurological disorders. Howard Weisman, CEO of PaxMedica, affirmed, "Our determination to progress with the NDA submission for PAX-101 remains unaffected, as does our commitment to our clinical program to further explore the potential for anti-purinergic therapies to address the core symptoms of autism spectrum disorder (ASD)." The com
- SECPaxMedica Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - PaxMedica, Inc. (0001811623) (Filer)
- PRPaxMedica's CEO and Malawi Health Official Discuss Urgent Medical Crisis in Bell2Bell PodcastLOS ANGELES, April 26, 2024 (GLOBE NEWSWIRE) -- via IBN -- IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. PaxMedica (NASDAQ:PXMD), a biopharmaceutical company dedicated to advancing treatments for neurological disorders, takes center stage in the episode. During this insightful conversation, Howard Weisman, CEO of PaxMedica, and Dr. Marshal Lemerani, Program Manager at the Malawi Ministry of Health, joined host Stuart Smith to di
- NEWSPaxMedica Responds To Emergency Request For IV Suramin; To Provide Immediate Access To PAX-101
- SECPaxMedica Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - PaxMedica, Inc. (0001811623) (Filer)
- PRPaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101TARRYTOWN, New York, April 23, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica Inc. (NASDAQ:PXMD) (the "Company"), a leading biopharmaceutical company dedicated to advancing treatments for neurological disorders, expects to take immediate action in response to an urgent request for IV suramin from the Ministry of Health (MOH) of Malawi, a country in east Africa. The request seeks emergency access to the Company's recently completed registration batches of PAX-101 (IV suramin) to address the critical shortage of medications required to combat the life-threatening sleeping sickness, also known as Trypanosoma brucei rhodesiense, Human African trypanosomiasis (TBr HAT), crisis in the region. How
- NEWS12 Health Care Stocks Moving In Friday's Pre-Market SessionGainers Chromocell Therapeutics (AMEX:CHRO) stock increased by 21.6% to $1.49 during Friday's pre-market session. The company's market cap stands at $8.7 million. Kineta (NASDAQ:KA) stock moved upwards by 16.62% to $0.57. The market value of their outstanding shares is at $6.2 million. Portage Biotech (NASDAQ:PRTG) shares moved upwards by 14.83% to $0.28. The company's market cap stands at $5.4 million. Erasca (NASDAQ:ERAS) stock rose 13.73% to $2.04. The company's market cap stands at $308.4 million. MSP Recovery (NASDAQ:LIFW) shares moved upwards by 13.25% to $0.94. The company's market cap stands at $14.9 million. As per the press release, Q4 earnings came out 4 days ago. Cue Health
- NEWSPaxMedica shares are trading higher after the company received an emergency request form the Ministry of Health of Malawi asking for emergency access to IV suramin.